FDA assures Transparency in Contraceptives Review
The Food and Drugs Administration (FDA) recently assured the public that the evaluation and reevaluation of contraceptives, including those covered by a Supreme Court order, “is aboveboard and transparent”. It also said that the results of the process “will be fully compliant with the standards set by the High Court”.
The assurance was issued by FDA Director-General Nela Charade Puno as the agency nears the completion of the review in line with the certification and recertification of some 50 contraceptives. Several of these contraceptives are covered by an SC order for recertification following a petition by a civic group.